Who Paid My Doc
Joselito Cabaccan
Endocrinology, Diabetes & Metabolism San Jose, CA Medical Doctor
NPI 1801813720 CMS profile 354123
2690 S White Rd, Ste 50, San Jose, CA 95148
General payments
$1,422,625
Research payments
$52,093
Ownership & investment interest
$0
Research they led as principal investigator
$6,001
Through program year 2025, Joselito Cabaccan of San Jose, CA is reported in the CMS Open Payments database as having received $1,422,625 across 4,063 general payments and $52,093 in research payments paid to them. Separately, studies naming them as principal investigator received $6,001 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $180,500 | 412 | |
| 2024 | General | $108,667 | 428 | |
| 2023 | General | $126,261 | 445 | |
| 2022 | General | $262,160 | 627 | |
| 2022 | Research | $220 | 1 | |
| 2021 | General | $208,767 | 627 | |
| 2021 | Research | $13,256 | 4 | |
| 2020 | General | $197,051 | 620 | |
| 2020 | Research | $27,634 | 74 | |
| 2019 | General | $339,218 | 904 | |
| 2019 | Research | $10,983 | 3 |
Beside peers
- Joselito Cabaccan
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Joselito Cabaccan were reported at $180,500. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Joselito Cabaccan | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $339,218 | $494 | $123–$2,253 | $163 |
| 2020 | $197,051 | $335 | $85–$1,841 | $114 |
| 2021 | $208,767 | $398 | $88–$1,981 | $132 |
| 2022 | $262,160 | $364 | $88–$1,568 | $149 |
| 2023 | $126,261 | $420 | $113–$1,614 | $160 |
| 2024 | $108,667 | $440 | $121–$1,646 | $164 |
| 2025 | $180,500 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 114 drugsPart D claims
14,351
Drug cost
$8,613,193
Branded share of claims
54.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 1,000 | $1,616,758 | |
| Jardiance Empagliflozin | Brand | 885 | $1,108,758 | |
| Trulicity Dulaglutide | Brand | 654 | $948,751 | |
| Mounjaro Tirzepatide | Brand | 507 | $701,640 | |
| Korlym Mifepristone | Brand | 12 | $465,403 | |
| Farxiga Dapagliflozin Propanediol | Brand | 371 | $413,617 | |
| Afrezza Insulin Regular, Human | Brand | 109 | $392,762 | |
| Rybelsus Semaglutide | Brand | 209 | $372,971 | |
| Kerendia Finerenone | Brand | 259 | $303,545 | |
| Humalog Kwikpen U-200 Insulin Lispro | Brand | 64 | $155,424 |
The 10 drugs with the highest cost, of 114 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 61 billing codesPaid by Medicare
$1,888,312
Medicare patients
2,206
Services billed
112,619
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 64% | |
| Osteoporosis | 46% | |
| Chronic kidney disease | 37% | |
| Arthritis | 36% | |
| Ischemic heart disease | 29% | |
| Atrial fibrillation | 17% | |
| Heart failure | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, romosozumab-aqqg, 1 mg J3111 | Office | 58 | 61,324 | $498,773 |
| Injection, denosumab, 1 mg J0897 | Office | 174 | 15,661 | $305,545 |
| Vaccine for influenza for injection into muscle 90653 | Office | 291 | 291 | $23,810 |
| Vaccine for influenza for injection into muscle 90662 | Office | 159 | 162 | $13,083 |
| Pcv20 vaccine im 90677 | Office | 18 | 18 | $4,968 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 89 | 437 | $2,026 |
| Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 | Office | 13 | 13 | $1,700 |
| Influenza vaccine, trivalent derived from recombinant dna 90673 | Office | 18 | 18 | $1,473 |
| Influenza vaccine, trivalent derived from cell cultures 90661 | Office | 11 | 11 | $397 |
| Injection, cosyntropin, 0.25 mg J0834 | Office | 14 | 14 | $249 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 43 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| MOUNJARO |
|
$45,201 | 507 | — |
| Kerendia |
|
$25,944 | 259 | — |
| JARDIANCE |
|
$12,246 | 885 | — |
| AFREZZA |
|
$4,855 | 109 | — |
| Ozempic |
|
$4,845 | 1,000 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 43 with PatronRecords
4,145 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in California
Juan Frias
Endocrinology, Diabetes & Metabolism · San Diego, CA
Daniel Nadeau
Endocrinology, Diabetes & Metabolism · Newport Beach, CA
Yehuda Handelsman
Endocrinology, Diabetes & Metabolism · Tarzana, CA
Helen Baron
Endocrinology, Diabetes & Metabolism · Rancho Mirage, CA
Ken Fujioka
Endocrinology, Diabetes & Metabolism · San Diego, CA
Minou Tran
Endocrinology, Diabetes & Metabolism · Pico Rivera, CA
Related records
Endocrinology, Diabetes & Metabolism in California
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.